Skip to content

The Safety and Efficacy of 1064-nm Picosecond Laser With Microlens Array for Pore Tightening; a Pilot Study

The Safety and Efficacy of 1064-nm Picosecond Laser 1064 With Microlens Array for Pore Tightening; a Pilot Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04471948
Enrollment
26
Registered
2020-07-15
Start date
2020-05-07
Completion date
2021-03-07
Last updated
2021-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Enlarged Pores

Brief summary

The objective of this study is to evaluate the safety and efficacy of 1064-nm Picosecond laser 1064 With Microlens Array for Pore tightening.

Detailed description

The Safety and Efficacy of Picosecond laser 1064 Nanometers With Microlens Array for Pore tightening; a Pilot Study Primary outcome : pore size Secondary outcome : side effect, patient satisfaction, global evaluation the patient recieved laser treament once a month for 3 months and then follow up after last treatment at 1, 3 ,6 month Enlarged facial pores is one of the skin signs in photoaging. There are 3 major clinical causes of enlarged facial pores: highs sebum excretion, decreased elasticity around pores and increased hair follicle volume. Possible causative factors of enlarged facial pores include many exogenous and endogenous factors include genetic predisposition, seborrhea and chronic ultraviolet light exposure. Picosecond laser are new device which has been used in skin rejuvenation. The main mechanism of action is laser induced optical breakdown (LIOB).

Interventions

DEVICEFractional picosecond 1064 nm laser

The parameter of laser was 8 mm spot size, 0.8 mJ/CM2, 750 ps, 5 Hz, 2 passes The treatment was done in every 4 weeks for 3 sessions.

Sponsors

Mahidol University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
25 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Both male and female age 25-40 years * No underlying disease

Exclusion criteria

* History of retinoid or other keratolytic drugs used within 6 months before enrolled * History of keloid * photosensitivity * Immunocompromised host

Design outcomes

Primary

MeasureTime frame
Change in pore size by Antera 3D imagechange from baseline in pore size at 6 months

Countries

Thailand

Contacts

Primary Contactworaphong Manuskiatti, M.D.
doctorlaser@gmail.com02-419-1000
Backup ContactSiriwan palawisuth, M.D.
siriwan_monk@yahoo.com02-419-1000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026